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Purpose/Objective: In our previous work[1], a multivariable 
normal tissue complication probability (NTCP) model for 
acute esophageal toxicity (AET) grade ≥2 after (chemo-
)radiotherapy (CRT) for non-small cell lung cancer (NSCLC) 
was developed for patients treated with intensity-modulated 
radiation therapy (IMRT), based on clinical risk factors and 3D 
dose-volume histogram (DVH) parameters of the esophagus. 
In this NTCP analysis, the esophagus was considered a ‘solid’ 
organ, whereas it seems more realistic to consider it as a 
‘hollow’ organ, and establish an NTCP model based on 2D 
dose-surface parameters. We investigated the hypothesis 
that incorporating 2D dose-surface data with and without 
spatial information improves the predictive power of our 
NTCP model based on 3D dose-volume data. 
Materials and Methods: For 149 advanced-stage NSCLC 
patients treated with IMRT, dose-surface histograms (DSHs) 
and polar dose-surface maps (DSMs) (Figure 1) were 
generated with an in-house developed MATLAB-based 
software tool.  
 
Parameters extracted from the DSHs include: a) conventional 
DSH without spatial information, b) contiguous DSH (cDSH) 
representing the largest connected surface area (CSA) 
receiving at least a certain dose, and c) combined cDSH 
representing all CSAs receiving at least a certain dose, scaled 
with decreasing weights for increasing distance to largest 
CSA. Parameters extracted for DSMs include: d) 
circumferential (transverse plane) dose-length histogram 
(cDLH) and e) longitudinal (cranio-caudal direction) dose-
length histogram (lDLH). Following our previous work[1], new 
multivariable NTCP models were developed with the MATLAB-
based DREES tool, consisting of 4 prognostic factors: 
concurrent chemoradiotherapy, gender, tumor stage and the 
most predictive DSH or DSM parameter from method a) to e) 
as identified by logistic regression analysis. Predictive 
performance of these NTCP models was assessed by the area 
under the curve (AUC) of the receiver operator characteristic 
(ROC) graph and by comparison with the established NTCP 
model. 
Results: Univariate logistic regression analysis identified the 
following parameters to show a highly significant correlation 
with AET: mean esophageal dose (MED) for a) DSH, b) cDSH, 
c) combined cDSH, and the maximum length of the 
esophageal surface receiving a contiguous dose ≥60 Gy (L60Gy) 
for d) cDLH and e) lDLH. Substituting MED for these 
parameters in the established NTCP model[1] resulted in AUCs 
of a) 0.83, b) 0.83, c) 0.82, d) 0.81, and e) 0.80, as compared 
to 0.84 found in the previous work based on 3D DVH data. 
Conclusions: Incorporating 2D dose-surface data with and 
without spatial information did not improve the predictive 
performance of the multivariable NTCP model based on 3D 
dose-volume data. 
[1] R. Wijsman, F. Dankers, E. Troost, A. Hoffmann, J. 
Bussink. Multivariable predictive modeling of esophageal 
toxicity after IMRT for advanced stage NSCLC. Submitted 
ESTRO 2015.  
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Purpose/Objective: CONVERT is an international randomised 
phase III trial, which recruited good performance status 
patients with limited-stage small cell lung cancer from April 
2008 until November 2013. 547 patients were recruited in 
total. Patients were randomised to receive 45Gy in 30 
fractions twice-daily (control arm) or 66Gy in 33 fractions 
once-daily (trial arm) given concurrently with 
cisplatin/etoposide. The primary endpoint was overall 
survival. 
In recent years the advancement of radiotherapy techniques 
has been particularly beneficial for lung radiotherapy with 
the aims of improving local control and reducing normal 
tissue complications. For example, imaging techniques such 
as 4DCT and PET CT have improved the accuracy of tumour 
and organ at risk delineation. Use of type B treatment 
planning algorithms is of particular importance in a low 
electron density region such as lung tissue. 
Here, we present some of the findings from a survey which 
was sent out to clinicians who had randomised patients into 
the CONVERT trial to establish what techniques were being 
used to plan and treat trial patients towards the end of the 
trial.  
Materials and Methods: A survey was sent out to 63 centres 
based in Belgium, Canada, France, Netherlands, Slovenia, 
Spain, Ireland and the UK who participated in the CONVERT 
Trial between April 2008 and November 2013. The survey was 
completed using the online survey tool – Survey Monkey. For 
the purpose of this study we focus on pre-treatment imaging, 
treatment planning and delivery technique and on treatment 
imaging techniques used by centres towards the end of the 
trial, and some country by country analysis.  
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Results: 42 out of the total of 63 centres completed the 
survey (66.7%). 
At the time of completing the questionnaire: 
· 19 (45.2%) centres were using 4DCT and 33 (78.6%) were 
using PETCT for tumour delineation. 
· 21 (50%) centres were treating lung patients with intensity 
modulated radiation therapy. 
· All centres were using a type B treatment planning 
algorithm. 
· 11 (26.2%) centres were using respiratory gating or breath 
hold techniques. 
30 (71.4%) centres were using cone beam computed 
tomography for treatment verification. 
Conclusions: During the 5 years the Convert Trial has been 
open there have been significant advances in lung 
radiotherapy treatment technology. Major changes include 
the use of 4DCT and PET CT to aid tumour delineation, use of 
type B treatment planning algorithms, IMRT for treatment 
delivery and CBCT for treatment verification of patients with 
small cell lung cancer.  
The survey results show some international variation in 
techniques available for planning and treating CONVERT 
patients (data to be presented at the meeting). 
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Purpose/Objective: Most normal tissue complication 
probability (NTCP) models for Acute Esophageal Toxicity 
(AET) after (chemo-)radiotherapy for non-small cell lung 
cancer (NSCLC) are based on three-dimensional conformal 
radiotherapy (3D-CRT). Intensity-modulated radiation therapy 
(IMRT), however, has different dosimetric characteristics 
requiring new NTCP model parameters. Therefore, we 
investigated the relationship between clinical risk factors and 
dose-volume histogram (DVH) parameters to establish an 
IMRT-based multivariable NTCP model for AET. 
Materials and Methods: In 149 advanced stage NSCLC 
patients treated with IMRT, the AET scores were analyzed in 
relation to clinical risk factors and IMRT-plan derived DVH 
parameters. The NTCP model for grade ≥2 AET was selected 
by multivariable logistic regression analysis. Firstly, we 
evaluated the correlation between the clinical risk factors 
and DVH parameters to assess multicollinearities. Secondly, 
DVH data were fitted to the Lyman-Kutcher-Burman (LKB) 
dose-response model to establish the parameter values for n, 
m and D50. Thirdly, the optimal model (order) was 
determined by bootstrap sampling. We finally evaluated the 
performance of the multivariable NTCP model by the area 
under the curve (AUC) of the receiver operator characteristic 
and calibrated the model with the Hosmer and Lemeshow 
test for agreement between the predicted and observed 
NTCP estimates. 
Results: We found a strong correlation between esophageal 
Dmean and a wide range of esophageal DVH parameters (such 
as V15Gy through V60Gy) suggesting a high degree of 
multicollinearity. Dmean was associated with grade ≥2 AET on 
univariate logistic regression analysis (p=0.001). The LKB 
model parameter values were n = 1.04 (95% CI 0.48-5.49), m 
= 0.65 (0.27-1.03), and D50 = 32.84 (15.59-50.08) Gy. The 
volume parameter (n=1.04) indicates a large volume effect 
implying that Dmean is a good predictor for AET. For these 
reasons, Dmean was the only robust DVH parameter included in 
the multivariable logistic regression analysis. 
The NTCP model showed an increased risk of grade ≥2 AET 
with concurrent chemotherapy (CCR) (odds ratio (OR) 14.08, 
95% CI 4.70-42.18; p<0.001), with increasing Dmean (OR 1.12 
per Gy increase, 95% CI 1.06-1.19; p<0.001), in female 
patients (OR 3.33, 95% CI 1.36-8.12; p=0.008) and with tumor 
stage ≥T3 (OR 2.7, 95% CI 1.12-6.49; p=0.026). Discriminative 
power was good with an AUC of 0.84 (95% CI 0.771–0.912). 
There was no difference between the predicted complication 
risk and the observed outcome (p=0.127), indicating that the 
model is well calibrated. 
Conclusions: A multivariable predictive model including the 
parameters CCR, Dmean, tumor stage and gender has a high 
predictive value for grade ≥2 AET after IMRT for advanced 
stage NSCLC. Validation of this model in an independent 
patient cohort is mandatory.  
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Purpose/Objective: Single-photon emission computed 
tomography (SPECT) can potentially be used to define 
functional lung regions (FL), but it remains unclear how the 
radiation dose to FL is related to the risk of radiation-induced 
lung toxicity after radiotherapy. The purpose of the study 
was to analyse dosimetric parameters in functional and non-
functional lung determined by SPECT, and to establish their 
role in risk of symptomatic lung toxicity after curative 
radiotherapy  
Materials and Methods: Patients undergoing definitive 
chemo-radiotherapy for non-small cell lung cancer were 
included prospectively. Perfusion SPECT/CT was performed 
before the treatment started. Regions of interest 
corresponding to 20, 40, 60 and 80% of maximum perfusion 
count (FL 20-80%) were created on SPECT and transferred to 
the planning CT (Figure 1). Functional dose-volume 
histograms (DVHf) for FL 20-80% were created. Primary 
clinical end-point was radiation pneumonitis (RP) graded by 
CTC-AE version 4. Functional DVH was compared with 
conventional DVH (DVHc). Association of DVHf parameters and 
functional mean lung dose (MLDf) for FL 20-80% with 
symptomatic radiation pneumonitis (CTC grade 2-5) was 
assessed.  
